NEW YORK, Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslr ...

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both da ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Bioscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug nimacimab [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [6]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives made false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical and commercial prospects [4]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss compared to placebo, leading to a significant stock price drop of 60%, closing at $1.90 per share [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm is actively seeking information regarding Skye's conduct from whistleblowers, former employees, and shareholders [7].

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Skye's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Skye Bioscience class action, go to www.faruqilaw.com/SKYE or call Far ...

Philadelphia, Pennsylvania--(Newsfile Corp. - December 22, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, nimacimab [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the effectiveness of nimacimab was overstated, leading to inflated clinical, regulatory, and commercial prospects [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug nimacimab [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives made false and misleading statements regarding nimacimab, claiming it was more effective than it actually is [6]. - Specific allegations include that nimacimab's clinical, regulatory, and commercial prospects were overstated, leading to materially false public statements [6]. Group 3: Stock Price Impact - Following the announcement on October 6, 2025, that nimacimab did not achieve its primary endpoint in a clinical study, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share [7].

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye securities during the class period because the Company allegedly misled investors regarding the viability of its lead drug candidate. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? According to the complaint, during the class peri ...